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Prospective risk of cancer and the influence of tobacco
use in carriers of the p16-Leiden germline variant
Thomas P Potjer1, Heidi E Kranenburg2, Wilma Bergman3, Wouter H de Vos tot Nederveen Cappel4,
Hester S van Monsjou5, Daniela QCM Barge-Schaapveld1 and Hans FA Vasen*,2,6
The p16-Leiden germline variant in the CDKN2A gene is associated with a high risk of melanoma and pancreatic cancer.
The aims of this study were to assess the risk of developing other cancers and to determine whether tobacco use would alter
cancer risk in carriers of such a variant. We therefore prospectively evaluated individuals with a p16-Leiden germline variant,
participating in a pancreatic surveillance programme, for the occurrence of cancer (n=150). Tobacco use was assessed at the
start of the surveillance programme. We found a significantly increased risk for melanoma (relative risk (RR) 41.3; 95%
confidence interval (CI) 22.9–74.6) and pancreatic cancer (RR 80.8; 95% CI 44.7–146). In addition, increased risks were
found for cancers of the lip, mouth and pharynx (RR 18.8; 95% CI 6.05–58.2) and respiratory tumours (RR 4.56; 95% CI
1.71–12.1). Current smokers developed significantly more cancers of the lip, mouth and pharynx, respiratory system and
pancreas compared with former and never-smokers. In conclusion, this study shows that carriers of a p16-Leiden variant have an
increased risk of developing various types of cancer, and smoking significantly increases the risk of frequently occurring cancers.
Smoking cessation should be an integral part of the management of p16-Leiden variant carriers.
European Journal of Human Genetics (2015) 23, 711–714; doi:10.1038/ejhg.2014.187; published online 17 September 2014
INTRODUCTION
Familial atypical multiple mole melanoma (FAMMM) syndrome is
an autosomal dominant tumour syndrome characterized by the
development of melanoma and dysplastic naevi of the skin. Up to
40% of FAMMM families harbour a germline variant in the
CDKN2A gene, making it the most frequently involved gene
in FAMMM syndrome.1 More than 65 different variants in
the CDKN2A gene have been identified worldwide.2 In the
Netherlands, the p16-Leiden variant, a 19-base-pair deletion
(c.225_243del19; RefSeq NM_000077.4), is the most common
CDKN2A germline variant.3 In a previous study,4 we demonstrated
that carriers of such a variant have an increased risk of developing
pancreatic cancer (15–20% lifetime risk). Since then a large cohort
of patients is under pancreatic surveillance.5
Several studies reported an increased risk of tumours other than
melanoma and pancreatic cancers for various CDKN2A germline
variants.6–10 However, these studies have used a variety of methodo-
logical approaches and some have been limited by inclusion of
heterogeneous groups or by failure to determine individual mutation
status. In addition, the influence of environmental factors (for
example, smoking) on the phenotypic variability in FAMMM syn-
drome is yet to be elucidated.
In the present study, we analysed the prospective risk of cancer
in a unique cohort of individuals with the same CDKN2A germline
variant (p16-Leiden). In addition, we examined the association




Individuals were included in this study on the basis of carrier status for the p16-
Leiden germline variant and participation in a pancreatic surveillance pro-
gramme, which consisted of a yearly abdominal MRI combined with magnetic
resonance cholangiopancreatography from the age of 45.5
A complete medical history was obtained at the start of the surveillance
study. Following this first visit, patients revisited the gastroenterologist annually,
at which point the occurrence of new cancers or other diseases was assessed.
For the current study, all medical records (with pathological confirmation)
were obtained for each individual from the electronic hospital information
system. Only cancers that occurred after the first contact were included in the
analysis. The study inclusion and follow-up period was from January 2000 to
April 2013. The follow-up time for each individual started from inclusion until
the last documented appointment with a medical specialist at the Leiden
University Medical Center, or the date of death.
Cancer risk estimates and statistical analysis
The prospectively observed cancers were classified by the International
Classification of Diseases code 10 (ICD-10). To calculate the expected number
of cancers, 5-year cancer incidence rates of matching ICD codes, specific for sex
and age, were obtained from the Netherlands Cancer Registry for the province
of South-Holland in the Netherlands.11 To calculate the expected number of
neuroendocrine tumours, national incidence rates were used for the period
2001–2010.12 The relative risks (RRs) were computed by dividing the observed
cancer numbers into each group by the expected cancer numbers. Confidence
intervals (CIs) for the RRs were calculated with the use of Poisson probabilities.
To compute the impact of tobacco use on cancer development, individuals
were classified as either ever-smokers (current or former) or never-smokers at
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inclusion in the study; χ2 analysis was used for comparison. Acquired data were
submitted to a public CDKN2A gene variant database (http://chromium.liacs.
nl/LOVD2/home.php; submission ID no. 0014954).
RESULTS
Patient characteristics
A total of 150 proven or implied carriers of the p16-Leiden germline
variant were included (64 males, median age at inclusion 51 years
(range, 36–72 years)). One hundred and forty-four individuals had a
proven p16-Leiden germline variant, including a homozygote for the
p16-Leiden variant. The remaining six individuals had at least one
melanoma in their medical history and a close relative with the p16-
Leiden germline variant, which makes them highly likely of being a
carrier (497% according to Bayesian probabilities). The median time
of follow-up was 43 months (range, 1–144 months; first to third
quartiles, 17–89 months). The total observation period was 682
person years.
Prospective tumours
A total of 47 prospective tumours were diagnosed in 36 (24%) of the
150 individuals. Owing to the relatively small numbers of observed
cancers, classification was based on organ system rather than
individual site, with the exceptions of melanoma and pancreatic
cancer. Table 1 shows the RRs for developing various types of cancer.
Melanoma and pancreatic cancers were the most frequently occurring
ones (n= 11 each, RR 41.3 (95% CI 22.9–74.6) and 80.8 (95% CI
44.7–146), respectively). When these tumours were excluded from the
analysis, the risk of developing any type of cancer remained
significantly increased (RR 4.31; 95% CI 2.91–6.37). The highest risks
were found for cancers of the lip, mouth and pharynx (RR 18.8; 95%
CI 6.05–58.2), respiratory tumours (RR 4.56; 95% CI 1.71–12.1) and
digestive tract tumours (RR 3.71; 95% CI 1.39–9.90). The relatively
small numbers of observed cancers, however, resulted in broad CIs,
which is especially true for cancers of the bone and soft tissue.
Details of 21 prospective cancers (all cancers except those of skin
and pancreas) are shown in Table 2. Notably, the observed number of
carcinoid tumours was higher than expected (0.0168; RR 119; 95% CI
29.7–475). When excluding carcinoid tumours from the risk
calculation for digestive tract tumours, the increased risk for a
digestive tract tumour no longer reached significance (RR 1.86; 95%
CI 0.465–7.43).
Seven individuals developed a total of 11 melanomas during the
follow-up period. However, a much larger number of individuals (91
out of 150) had a diagnosed melanoma before starting surveillance for
pancreatic cancer (median age at diagnosis of first melanoma 40 years).
Table 3 shows tumours diagnosed before inclusion, of which melanoma
forms by far the major part. Only one individual developed a first
melanoma during the follow-up period. Melanoma therefore remains
the most frequently occurring cancer in this p16-Leiden study cohort
and first melanomas mostly occur before the age of inclusion (45 years).
A more exhaustive description of the melanoma phenotype in carriers
of the p16-Leiden germline variant is given by van der Rhee et al.13
Tobacco use
With regard to a personal history of smoking, information was
complete for 147 (98%) out of 150 individuals. At inclusion, 92
individuals were ever-smokers (of which 26 were current smokers).
Eleven of the 92 ever-smokers (12%) and 4 of 55 never-smokers (7%)
developed pancreatic cancer, respiratory cancer or cancer of the lip,
mouth and pharynx (P= 0.364). Four of the eleven patients with
pancreatic cancer were never-smokers. When only current smokers
were considered, 7 of 26 (27%) developed the above mentioned
cancers, versus only 8 of 121 (7%) of the former and never-smokers.
Therefore, current smokers in our cohort have a fourfold increased
risk of developing these types of cancer when compared with former
and never-smokers (P= 0.002).
Chronic diseases
We also evaluated the occurrence of other (chronic) diseases. We
found that 6 out of 150 individuals (4%) had a medical history of
sarcoidosis, which is much higher than expected (estimated prevalence
in Europe is ~ 15–20 per 100 000 individuals).14 There was no kinship
between these individuals.
Causes of death
Eighteen of the 150 individuals died during follow-up (median age of
death was 62 years (range, 49–78 years)). Seventeen individuals died
Table 1 Relative risk of developing cancer in a prospective series of p16-Leiden variant carriers (n=150)
Site/organ system ICD-10 code Observed (95% CI) Expected RR (95% CI)
Bone c40-c41 1 (0.141–7.10) 0.0149 66.9 (9.43–475)a
Digestive c15-c24, c26 4 (1.50–10.7) 1.08 3.71 (1.39–9.90)a
Female breast c50 3 (0.967–9.30) 1.15 2.61 (0.840–8.08)
Haematological c81-c96 1 (0.141–7.10) 0.462 2.16 (0.305–15.3)
Lip, mouth, pharynx c00-c14 3 (0.968–9.30) 0.160 18.8 (6.05–58.2)a
Male genital c60-c63 1 (0.141–7.10) 0.689 1.45 (0.204–10.3)
Melanomab c43 11 (6.09–19.9) 0.266 41.3 (22.9–74.6)a
Nonmelanoma skinc c44 4 (1.50–10.7) 0.327 12.3 (4.60–32.6)a
Pancreas c25 11 (6.09–19.9) 0.136 80.8 (44.7–146)a
Respiratory c32-c34 4 (1.50–10.7) 0.877 4.56 (1.71–12.1)a
Soft tissue c38, c47-c49 2 (0.500–8.00) 0.0336 59.5 (14.9–238)a
Unknown primary site c80 1 (0.141–7.10) 0.138 7.22 (1.02–51.3)
Urinary c64-c68 1 (0.141–7.10) 0.333 3.00 (0.423–21.3)
All cancers 47 (35.3–62.6) 6.20 7.58 (5.69–10.1)a
All cancers except melanoma and pancreas 25 (16.9–37.0) 5.80 4.31 (2.91–6.37)a
aSignificant.
bBasal cell carcinoma is not registered in the NCR and therefore not included in the calculation.
cFirst as well as subsequent melanomas are registered In the Netherlands Cancer Registry (NCR).
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from cancer; seven from pancreatic cancer (median age 59 years) and
four from melanoma (median age 61 years).
DISCUSSION
This prospective study analysed the risk of cancers in a cohort of
homogeneous CDKN2A variant carriers (p16-Leiden). A significantly
increased risk of both melanoma and pancreatic cancers was found.
However, when excluding these cancers from the risk calculation, a
marked increased risk for developing any cancer (RR 4.31; 95% CI
2.91–6.37) remained. Most notable were the increased risk of
respiratory and lip, mouth and pharynx cancers, and the relatively
frequent occurrence of carcinoid tumours. Being a current smoker at
the start of surveillance was significantly associated with the develop-
ment of tumours of the pancreas, respiratory tract and head and neck
regions. In addition, we found an association between the p16-Leiden
variant and sarcoidosis.
Without considering melanoma and pancreatic cancer, tumours of
the respiratory tract (including laryngeal tumours) and of the lip,
mouth and pharynx were the most frequently occurring tumours in
our cohort. A previous retrospective study by de Snoo et al.6 also
found significantly increased risks for these tumours in a cohort of
p16-Leiden variant carriers. Oldenburg et al15 described a p16-Leiden
variant-positive family in which many relatives had developed lung
cancer and head and neck tumours. Several other case reports have
also described the occurrence of head and neck tumours in CDKN2A
variant-positive families.16,17 In sum, it seems that tumours of the
head and neck and the respiratory tract are part of the spectrum of
cancers occurring in CDKN2A variant-positive FAMMM families.
Two interesting observations were the relatively frequent occurrence
of carcinoid tumours and sarcoidosis in unrelated variant carriers in
our cohort. Both have not been previously reported in carriers of a
CDKN2A variant. Although only two individuals developed a carci-
noid tumour during follow-up, another individual had a medical
history of carcinoid. It has been shown that CDKN2A inactivation has
a role in the pathogenesis of sporadic neuroendocrine tumours, as a
substantial amount of these tumours show loss of p16 protein
expression,18 and also promoter methylation of the CDKN2A gene
is frequently found.19 Further studies are needed to confirm the
possible association between a CDKN2A germline variant and
carcinoid tumours or sarcoidosis.
Our current study has several strengths. Owing to its prospective
design, patient participation was not influenced by the occurrence of
tumours. In addition, because of the yearly follow-up at the outpatient
Department of Gastroenterology, it is unlikely that cancers and other
important medical information were missed. Another strength is the
homogeneity of the cohort; all individuals have the same CDKN2A
germline variant. An important limitation was, however, the relatively
high age of inclusion of individuals (median age 51 years), which was
because of the threshold of 45 years of age for inclusion in the
pancreatic surveillance programme. Tumours generally occurring
before this age were therefore not included in the calculations, which
is reflected by the observation of a high incidence of melanoma before
start of the surveillance programme. As the number of participants
and observed cancers was relatively small, risk factor analysis for each
cancer separately could not be carried out.
Pancreatic cancer is the leading cause of death in our cohort.
Pancreatic cancer surveillance may improve survival, as most tumours
are detected in a resectable stage.5 In view of the increased risk of head
and neck tumours (including tumours of the larynx), patients should
be advised to contact their doctor if they have complaints of
hoarseness, dysphagia or ulcers in the mouth or throat. A low
threshold for reference to an otolaryngologist should be advocated.
A surveillance programme for tumours of the head and neck regions
should possibly be considered in the future, which could simply
consist of yearly inspection of the mouth and throat. The clear relation
of many of the frequently occurring cancers in our cohort to smoking
indicates that active intervention to quit smoking is of the utmost
importance in this group.
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1 F Caecum Carcinoid 72
2 M Appendix Carcinoid 58
Bone Papillary squamous cell
carcinoma of mandible
62
3 M Stomach Adenocarcinoma of cardia 64
4 M Haematopoietic Multiple myeloma 67
Stomach Adenocarcinoma 67
5 F Breast Ductal adenocarcinoma 48
6 F Breast Ductal adenocarcinoma 53
7 F Breast Ductal adenocarcinoma 49
8 M Hypopharynx Squamous cell carcinoma 51
Lung Squamous cell carcinoma 52
9a M Floor of mouth Squamous cell carcinoma 58
Larynx Squamous cell carcinoma 58
10 F Tongue Carcinoma not specified 51
11 F Lung Non-small cell carcinoma 60
12 M Larynx Squamous cell carcinoma 55
13 F Bladder Small cell carcinoma 58
14 M Prostate Adenocarcinoma 69
15 F Knee Myxofibrosarcoma 48
16 M Neck Leiomyosarcoma 66
17 F Unknown Metastatic adenocarcinoma 67
aThis patient had two primary tumours detected concurrently.
Table 3 Tumours diagnosed before inclusion in the surveillance
programme
Site/organ system Observed cancer Individual(s)
Digestive 1 1
Female breast 4 4
Female genital 1 1
Lip, mouth, pharynx 3 2
Melanoma 194 91
Nonmelanoma skin 2 2
Respiratory 4 4
Urinary 1 1
All cancers 210 98
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